PARC Projects

Provide protection against most harmful chemicals
Shift away from animal testing
Innovative testing strategies for the developing immune system
Health effects
Human health
NGRA
Time span
-
Potential impacts
  • Reduce the reliance on animal testing to understand the toxic properties of chemicals
  • Prevention of immune related diseases like allergies and autoimmune disorders and chronic inflammation
  • Reduce the exposure to immunotoxic chemicals
Partners involved
INSERM (FR)
NIPH (NO)
IUF (DE)
LIH (LU)
MUI (AT)
UFZ (DE)
RIVM (NL)
NCPHP (HU)
NMBU (NO)
UMIL (IT)
Contacts
Saadia Kerdine-Römer (INSERM)
saadia.kerdine-romer [at] universite-paris-saclay.fr
Birgitte Lindeman (NIPH)
Birgitte.lindeman [at] fhi.no
Nicola M. Smith (NIPH)
Nicolamargareta.smith [at] fhi.no
Key messages
  • The developing immune system is highly sensitive and vulnerable to harmful substances in the environment- This project will help create better (non-animal) testing methods to detect and understand these risks and protect immune health.
Overview

This project expands the ongoing PARC immunotoxicity work to focus on the effects of chemicals on the developing immune system. It aims to fill critical regulatory gaps by developing better tools to detect harmful chemicals, especially those that impact the highly sensitive developing immune system.

The project supports the EU’s Chemicals Strategy for Sustainability by identifying vulnerable stages in immune system development, improving test methods, and supporting decisions on chemical safety. It uses New Approach Methodologies (NAMs) and builds on existing immunotoxicity assays, some already validated under OECD guidelines.

In the short term, the project will:

  • map sensitive stages in immune development;
  • use and refine existing assays and NAMs to support regulatory decisions;
  • improve decisions on when to include DIT testing in studies.

In the long term, the project will aim to develop new NAMs to fully replace animal testing and better detect developmental effects. It collaborates with the CAAT-led “Alternatives to in vivo Developmental Immunotoxicity Testing” and works closely with regulatory bodies like ECHA to ensure relevance for REACH, CLP, and other EU regulations.

By focusing on children and prenatal exposure, the project addresses growing health concerns such as allergies, autoimmune diseases, and infections. The DIT project aims to create a more robust, ethical, and science-based approach to chemical safety and public health protection.

Policy relevance
  • Adress the needs identified by ECHA in the KARC document (Key Areas of Regulatory Challenge) ultimately making progress towards the long-term goal of a comprehensive battery of tests to screen, prioritize and risk assess chemicals.
Filter by
Address chemical pollution in the natural environment
Provide protection against most harmful chemicals
Shift away from animal testing
Biodiversity protection
Streamlining data processing methods for suspect and non-target screening
Environment
Health effects
Human health
Monitoring methods
Risk assessment
NGRA
Mixtures
Human biomonitoring
Workers
Streamlining data processing methods for suspect and non-target screening
Streamlining data processing methods for suspect and non-target screening

Innovative testing strategies for the developing immune system

Time span
-
Potential impacts
  • Reduce the reliance on animal testing to understand the toxic properties of chemicals
  • Prevention of immune related diseases like allergies and autoimmune disorders and chronic inflammation
  • Reduce the exposure to immunotoxic chemicals
INSERM (FR)
NIPH (NO)
IUF (DE)
LIH (LU)
MUI (AT)
UFZ (DE)
RIVM (NL)
NCPHP (HU)
NMBU (NO)
UMIL (IT)
Key messages
  • The developing immune system is highly sensitive and vulnerable to harmful substances in the environment- This project will help create better (non-animal) testing methods to detect and understand these risks and protect immune health.
Overview

This project expands the ongoing PARC immunotoxicity work to focus on the effects of chemicals on the developing immune system. It aims to fill critical regulatory gaps by developing better tools to detect harmful chemicals, especially those that impact the highly sensitive developing immune system.

The project supports the EU’s Chemicals Strategy for Sustainability by identifying vulnerable stages in immune system development, improving test methods, and supporting decisions on chemical safety. It uses New Approach Methodologies (NAMs) and builds on existing immunotoxicity assays, some already validated under OECD guidelines.

In the short term, the project will:

  • map sensitive stages in immune development;
  • use and refine existing assays and NAMs to support regulatory decisions;
  • improve decisions on when to include DIT testing in studies.

In the long term, the project will aim to develop new NAMs to fully replace animal testing and better detect developmental effects. It collaborates with the CAAT-led “Alternatives to in vivo Developmental Immunotoxicity Testing” and works closely with regulatory bodies like ECHA to ensure relevance for REACH, CLP, and other EU regulations.

By focusing on children and prenatal exposure, the project addresses growing health concerns such as allergies, autoimmune diseases, and infections. The DIT project aims to create a more robust, ethical, and science-based approach to chemical safety and public health protection.

Policy relevance
  • Adress the needs identified by ECHA in the KARC document (Key Areas of Regulatory Challenge) ultimately making progress towards the long-term goal of a comprehensive battery of tests to screen, prioritize and risk assess chemicals.
Contacts
Saadia Kerdine-Römer (INSERM)
saadia.kerdine-romer [at] universite-paris-saclay.fr
Birgitte Lindeman (NIPH)
Birgitte.lindeman [at] fhi.no
Nicola M. Smith (NIPH)
Nicolamargareta.smith [at] fhi.no
Topics
Provide protection against most harmful chemicals
Shift away from animal testing
Keywords
Health effects
Human health
NGRA